Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials

Publication date: Available online 27 February 2016
Source:Critical Reviews in Oncology/Hematology
Author(s): Giandomenico Roviello, Sandra Sigala, Romano Danesi, Marzia del Re, Alberto Bonetta, Maria Rosa Cappelletti, Laura Zanotti, Alberto Bottini, Daniele Generali
Abiraterone acetate and orteronel are two CYP-17 inhibitors that have been studied in prostate cancer. They have shown relevant toxicities, including fluid retention/oedema, hypokalaemia, hypertension, liver function test abnormalities and cardiac events. The goal of this study was to determine the risk of special adverse events related to CYP- 17 inhibitor in patients with metastatic castration-resistant prostate cancer (CRCP). Summary data from four randomized phase III trials comparing CYP-17 inhibitors and prednisone versus placebo and prednisone in metastatic CRCP patients were meta-analysed. Pooled risk ratios (RRs) for the risk of all-grade and grade 3–4 adverse events of special interest were calculated. Data from 4916 patients (2849 in the AA experimental arm; 2067 in the control arm) were analysed. The incidence of grade 3 to 4 adverse events was never more than 10% of the patients. However, compared with placebo, the CYP-17 inhibitor significantly increased the all-grade events of hypertension (RR=1.53; 95% CI=1.3–1.8; p<0.00001), hypokalaemia (RR=1.56; 95% CI=1.29–1.89; p<0.00001), cardiac disorders (RR=1.47; 95% CI=1.27–1.7; p<0.00001) liver function test abnormalities (RR=1.93; 95% CI=1.15–3.24; p=0.01) grade ≥3 adverse events, hypokalaemia (RR=4.23; 95% CI=1.28–13.99; p=0.02) and cardiac disorders (RR=1.55; 95% CI=1.18–2.05; p=0.002). A lot of adverse events such as hypertension, hypokalaemia, cardiac disorders and liver function test abnormalities are increased during CYP-17 inhibitor based therapy. Strict monitoring of these side effects should be considered during CYP- 17 inhibitor therapy in prostate cancer patients.



from Cancer via ola Kala on Inoreader http://ift.tt/1TqDQo3
via IFTTT